ALSF is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The RUNX1 Research Program (runx1.com) is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloid leukemia (AML) due to germline RUNX1 mutations with the ultimate goal of developing effective therapies to prevent the onset of AML.
ALSF and RUNX1 Research Program have partnered to raise awareness and accelerate research around familial RUNX1 disorders by creating two grant categories:
Familial RUNX1 Research Grant: Up to $250,000 over two years
The purpose of the grant is to fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with FPD/AML. Projects should focus on leukemia caused by familial RUNX1 mutations rather than sporadic AML with somatic RUNX1 mutations.
The Program is viewed as a long-term endeavor of collaboration and data sharing. We are especially interested in innovative and cross-disciplinary approaches to developing effective therapies.
Please complete a one-time New User registration. You will create your institution account, contact record and portal username/password. An email confirmation will be sent to verify your email address, completing your registration. Then login to access the grant application. NOTE: IE browser is incompatible with the online system; please use Chrome or Firefox for best results!